Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Sorrento Therapeutics, Inc. (OTCBB: SRNE; STI) and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO). The abstract (#e15076), entitled "Evaluation of a non-biologic nanoparticle form of paclitaxel in metastatic pancreatic cancer" was chosen for inclusion online in the ASCO 2013 Annual Meeting Proceedings, a Journal of Clinical Oncology supplement, and was released at on May 15, 2013. The abstract was authored by Kouros Motamed , Larn Hwang, Chao Hsiao , and Vuong N. Trieu .

A Phase I clinical trial established a maximum tolerated dose (MTD) for CynviloqTM of 300 mg/m2  when given every 3 weeks in combination with weekly dosing of 1250 mg/m2 gemcitabine as first line treatment for patients with advanced pancreatic cancer. Moreover, 5 out of 16 patients (31.3%) had confirmed complete responses (CR) or partial response (PR) with 95% exact confidence intervals (CI) of 11.0 and 58.7, respectively. The median progression-free survival (PFS) time was 5.6 months (95% CI = 2.9). The median overall survival (OS) time could not be estimated as the survival rate did not fall below 50%.

"Based on the data generated to date, we believe CynviloqTM  in combination with gemcitabine may offer beneficial dosing regimens and potent anti-tumor activity in patients with advanced pancreatic cancer", said Vuong Trieu , Ph.D., chief executive officer of IGDRASOL.


Sorrento Therapeutics, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Intranasally delivered neutralizing antibody protects against SARS-CoV-2 Omicron and Delta variants